相关实验视频
Updated: Feb 10, 2026
09:39
Assessing Specificity of Anticancer Drugs In Vitro
Published on: March 23, 2016
9.8K
双有效载荷的小分子药物合物使旁观者抗癌活性具有减少的非特异性释放
Chuanjie Chen1, Yongzhang Pan2, Na Zhang3
1Drug Discovery & Development Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 211112, China.
概括
小分子药物合物 (SMDCs) 的新双有效载荷策略增强了瘤杀伤效果并降低了毒性. 这种方法,由Bi-LIVTAC (XZ1618) 证明,显示了下一代向癌症治疗的前景.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 药物运输 药物运输 药物运输
背景情况:
- 小分子药物合物 (SMDCs) 显示出治疗前景,但由于有效性和安全性问题有限,临床转化面临挑战.
- 目前SMDC的优化策略主要侧重于连接体设计和链接体化学,留下了更广泛改进的潜力.
- SMDC有效载荷的目标外扩散有助于系统毒性,需要新的方法来提高安全性和有效性.
研究的目的:
- 引入和验证SMDCs的双有效载荷策略,以提高治疗疗效并最大限度地减少目标外扩散.
- 评估一个具有代表性的双有效载荷SMDC,Bi-LIVTAC (XZ1618) 在向细胞毒性,旁观者效应和非向吸收方面的性能.
- 在一个相关的临床前癌症模型中评估XZ1618的体内疗效和安全性.
主要方法:
- 设计和合成一个双有效载荷SMDC (Bi-LIVTAC,XZ1618) 具有两个降解器有效载荷.
- 在体外评估向细胞毒性和旁观者效应,以及测量受体独立吸收.
- 在Huh-7异种移植模型中,XZ1618与sorafenib结合的体内评估,监测瘤回归,血液毒性和器官损伤.
主要成果:
- 与传统的SMDC相比,XZ1618显示了增强的向细胞毒性和显著的旁观者效应.
- 通过双有效载荷设计,受体独立吸收量大幅减少,这表明目标特异性得到了改善.
- 在Huh-7异种移植模型中,XZ1618与sorafenib结合实现了完整的瘤回归,没有显著的血液或器官毒性.
- 双有效载荷策略被证明广泛适用于不同的膜受体和有效载荷类型.
结论:
- 双有效载荷战略代表了开发先进的SMDC的多功能和可翻译的平台.
- 这种方法通过提高疗效和减少全身毒性,显著扩大了SMDCs的治疗窗口.
- 使用双有效载荷设计的下一代SMDC具有改善癌症治疗结果的巨大潜力.
相关概念视频
02:09Bystander Effect
10.3K
The discussion of bullying highlights the problem of witnesses not intervening to help a victim. This is a common occurrence, as the following well-publicized event demonstrates. In 1964, in Queens, New York, a 19-year-old woman named Kitty Genovese was attacked by a person with a knife near the back entrance to her apartment building and again in the hallway inside her apartment building. When the attack occurred, she screamed for help numerous times and eventually died from her stab wounds.
10.3K
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.6K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.6K
02:50Conjugated Proteins
28.9K
Simple proteins and protein complexes contain only amino acids. In contrast, many other proteins, called conjugated proteins, covalently bond with non-protein moieties.
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
28.9K
02:50Conjugated Proteins
3.2K
3.2K
01:10In Vitro Drug Release Testing: Overview, Development and Validation
363
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
363
01:28Energy-releasing Steps of Glycolysis
147.1K
Glycolysis is divided into two phases based on whether energy is utilized or released. While the first phase consumes ATP, the second phase produces energy in the form of ATP and NADH. The energy is released over a sequence of reactions that turns G3P into pyruvate. The energy-releasing phase—steps 6-10 of glycolysis—occurs twice, once for each of the two 3-carbon sugars produced during steps 1-5 of the first phase.
The first energy-releasing step—the 6th step of glycolysis...
The first energy-releasing step—the 6th step of glycolysis...
147.1K